Tools   Select Another Resource Report Type

http://www.seqwright.com/clinicaltrialservices/biorepository.html

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks, which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute''s (NCI''s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester''s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone., documented on August 17, 2021.Convenient, cost-effective and reliable storage solutions including maintaining, storing and monitoring your biological samples. Avoid costly purchases of ultra-low temperature freezers, sample tracking LIMS, and layers of emergency back-up infrastructure. Enjoy peace of mind in the knowledge that your critical samples are safe, secure, and readily available to you. Service Features * Real-time sample tracking and monitoring, with 24/7 accessibility. * GLP compliant repository with cold chain of custody. * Numerous storage options, from ambient temperature to -170 degrees C. * Hazardous specimen storage capabilities. * Redundant emergency back-up systems. * Secure-access facility. * At Temperature back-up freezers. * Rapid domestic & international shipping. As a full-service contract genomics provider, SeqWright is able to offer our BioRepository customers the additional benefit of a broad portfolio of regulated services for testing of samples, as and when required, and then returning the samples back to our BioRepository for further storage. Contact us for your customized solution.

Proper citation: SeqWright Biorepository (RRID:SCR_004657) Copy   

•   Source: SciCrunch Registry
  

http://www.ebi.ac.uk/uniprot/unisave/?help=0&session=

The UniProtKB Sequence/Annotation Version Archive (UniSave) is a repository of UniProtKB/Swiss-Prot and UniProtKB/TrEMBL entry versions. Entries can be retrieved by entering a primary accession number or an entry name and pressing the Go! button. The result of the query is a list of entry versions with the UniProtKB database name, entry status, primary accession number, entry name, entry version, sequence version, release number and the release date, ordered by the release date, the latest version first. The entry version status can be ''''incorporated'''', ''''active'''', ''''changed'''', ''''replaced'''' or ''''deleted''''. An incorporated entry version is the first entry version added into UniProtKB, an active entry version is part of the latest public release, a changed entry version has been superseded by a newer entry version, a replaced entry has become secondary to another entry, and a deleted entry has been removed from the UniProtKB without becoming secondary to any other entry. For replaced entry versions, the status ''''Replaced'''' can be clicked to return all entries, which have the given entry as a secondary entry. If a date is provided as part of the query then only the version of the entry that was current at that date is displayed. Entries can be viewed by clicking ''''View'''' in the query results table. The ''''<< Earlier'''' and ''''Later >>'''' links can be used to access the earlier and later entry versions. The ''''Back to List'''' link returns the user to the query results table. Selecting ''''UniProtKB'''' or ''''Fasta'''' and pressing ''''Save'''' downloads the entry in flat file or fasta format. Comparison between entry versions is straightforward: selecting two entries and clicking the ''''Compare Selected'''' button will show the differences between the two entries. Whenever comparisons are made a Smith-Waterman sequence alignment is computed using SSEARCH, and displayed at the bottom of the entry. The actual alignment is displayed only when the sequences are not identical.

Proper citation: UniSave (RRID:SCR_004946) Copy   

•   Source: SciCrunch Registry
  

http://www.phosphonet.ca/

PhosphoNET is an open-access, online knowledgebase developed by Kinexus Bioinformatics Corporation to foster the study of cell signaling systems to advance biomedical research in academia and industry. PhosphoNET is the world''s largest repository of known and predicted information on human phosphorylation sites, their evolutionary conservation and the identities of protein kinases that may target these sites. Search by protein name, UniProt number, IPI number, or 15 AA P-site sequence. PhosphoNET presently holds data on over 650,000 known and putative phosphorylation sites (P-sites) in over 23,000 human proteins that have been collected from the scientific literature and other reputable websites. Over 14% of these phospho-sites have been experimentally validated. The rest have been predicted with a novel P-Site Predictor algorithm developed at Kinexus with academic partners at the University of British Columbia and Simon Fraser University. With the PhosphoNET Evolution module, this website also provides information about cognate proteins in over 20 other species that may share these human phospho-sites. This helps to define the most functionally important phospho-sites as these are expected to be highly conserved in nature. With the Kinase Predictor module, listings are provided for the top 50 human protein kinases that are likely to phosphorylate each of these phospho-sites using another proprietary kinase substrate prediction algorithm developed at Kinexus. Our kinase substrate predictions are based on deduced consensus phosphorylation site amino acid frequency scoring matrices that we have determined for each of ~500 different human protein kinases. The specificity matrices are generated directly from the primary amino acid sequences of the catalytic domains of these kinases, and when available, have proven to correlate strongly with substrate prediction matrices based on alignment of known substrates of these kinases. The higher the score, the better the prospect that a kinase will phosphorylate a given site. Over 30 million kinase-substrate phospho-site pairs are quantified in PhosphoNET. Kinexus Bioinformatics Corporation has the capability to test most of these putative interactions in vitro for our clients.

Proper citation: PhosphoNET (RRID:SCR_013070) Copy   

•   Source: SciCrunch Registry
  

http://publicationslist.org/index.html

PublicationsList.org exists to let researchers and research organizations maintain a reliable web-based record of their academic output without any fuss. Free for individual use; subscription for additional services and institutional sites. PublicationsList.org was set up to streamline the process of maintaining a professional academic publications list online with an easy to use web front end which any researcher can use to maintain their own, professional looking list of publications, which can be hosted on publicationslist.org, or embedded within a departmental web page. Links to full text preprints, or versions in open access repositories and journal websites can be included. Publicationslist.org now offers solutions for research groups and universities to archive and disseminate their research output. The emphasis on ease of use and intuitive user interaction that appeals so much to individuals provides an effective means for organizations to gather and manage research content without having to worry about user interface design themselves. There is a built in PubMed search interface for finding publications matching your name and selecting and importing the ones you want. All the fields will be fetched automatically from MedLine, including the abstract and keywords where available. In the data entry page there is an area where you can paste an entry from the reference management software and have the form automatically populated. You can also upload a complete bibliography file to add all the papers in one go. The supported formats are: EndNote, Reference Manager, BibTeX, ProCite, US Library of Congress XML (MODS), ISI, with conversions performed by bibutils.

Proper citation: PublicationsList.org (RRID:SCR_004164) Copy   

•   Source: SciCrunch Registry
  

http://ari.ucsf.edu/programs/asb.aspx

The AIDS Specimen Bank (ASB) provides repository services to cohort studies such as the Women''s Interagency HIV Study (WIHS), Primary HIV Infection Study, Staying Well Study, clinical trials performed at UCSF, and others. The majority of ASB clients are HIV investigators, but the bank also processes and stores specimens collected from some non-HIV studies. The ASB is also the Specimen Bank Core for the UCSF/GIVI Center for AIDS Research. The mission of the AIDS Specimen Bank is to provide the following: * Processing and handling of specimens * Short-term or long-term storage (includes ultra-low temperatures and liquid nitrogen) * Data management * Well-characterized specimens to qualified investigators for translational research * Consultation to investigators inquiring about specimen collection and storage * International resource for HIV research * Networking tool within the research community All body fluids����??sera, plasma, saliva, vaginal lavage, etc.����??are stored as 1-milliliter aliquots in ultra-low freezers (-70��������C). PBMCs are processed and stored in liquid nitrogen. All equipment involved with the processing of specimens (centrifuges and Coulter counter) is calibrated by trained technicians. The ASB is a participant in the Adult AIDS Clinical Trials Group PBMC Cryopreservation and Viability Panel, in which sets of processed and frozen PBMCs are sent to the Immunology Quality Assessment Program (IQA) testing lab for viability and cell counts. Our laboratory has participated in the IQA program for three years, and all samples have proven to be acceptable to their standards. The ASB is compliant with Good Laboratory Practices guidelines.

Proper citation: UCSF AIDS Specimen Bank (RRID:SCR_004981) Copy   

•   Source: SciCrunch Registry
  

http://jdrfconsortium.jaeb.org/

Consortium aiming to accelerate the development of systems for automated control of blood glucose in patients with diabetes. Consortium investigators seek to research and develop strategies, which can be commercialized, that will confer the long-term benefits of improved glycemic control by combining novel automated control algorithms and hormone therapies with continuous glucose monitors and pump devices. The field of closed-loop artificial pancreas research requires expert diabetologists partnering with expert mathematicians and engineers. Consortium investigators include endocrinologists and control theorists at research institutions in the US and in Europe. Many of the diabetes device manufacturers have also participated, providing pumps and sensors with enhanced capabilities that allow for closed-loop experiments to be performed. The goals of the consortium include: * Design, optimization, and clinical testing of multiple algorithmic approaches to closed-loop control * An in silico simulation platform, accepted by the FDA, for validating candidate closed-loop control algorithms in place of animal trials * Reusable templates for constructing the Investigational Device Exemption regulatory documents that must be approved by the FDA prior to any in-clinic, computer-assisted, closed-loop control research involving people * A modular software platform-the Artificial Pancreas System-with a protocol-independent user interface and hooks to incorporate an arbitrary control algorithm and control various continuous glucose monitors and pump devices * A secure consortium Web site with a central repository for experimental data and interfaces to submit candidate control algorithms for centralized validation and to upload or download clinical data sets * the first outpatient studies of an overnight controller * the first outpatient studies of a hypoglycemia minimization strategy * the development and testing of a modular treat-to-range closed-loop approach * multiple studies of dual hormone (insulin and glucagon) devices and a means to improve insulin kinetics Ongoing and recently completed in-clinic studies at the end of 2011 include investigations into hypoglycemia prediction and avoidance as well as fully-automated closed-loop control investigations using MPC and PID/PD-based algorithms. The most recent developments include the first-ever feasibility trials of portable, outpatient-based closed-loop control systems.

Proper citation: JDRF Artificial Pancreas Project Consortium (RRID:SCR_004010) Copy   

•   Source: SciCrunch Registry
  

http://www.oncoreuk.org/

No longer functioning as an independent charity, onCore UK is a national cancer biobanking organization. Our mission is to serve as an action team that informs, coordinates and develops cancer biobanking to enable research towards the discovery and development of new interventions against cancer. We also offer advice to researchers who need to collect and store samples for their own specific projects. Our main strategic objectives are: * To empower research using human biosamples to find new and effective means of preventing, detecting or treating cancer. * To improve access by researchers to the human biosamples they require for their work. * To facilitate an environment in which patients, the public, health professionals, researchers, funders of research, policy makers and regulators can work together to support cancer biobanking and the research it underpins. * To provide practical information, coordination and development for current and future people and organizations involved in cancer biobanking to ensure that they are not unnecessarily hindered in their work. * To provide an accurate and regularly updated picture of the cancer biobanking provision in the UK that will inform future decisions by funders supporting research using donated human biosamples. * To distribute the human biosamples that onCore UK has in its custody. onCore UK conducts its business within the overall scope of the National Cancer Research Institute (NCRI) and for the benefit of cancer research. In the past we have also worked with selected NHS hospitals in different parts of the country to collect biosamples and relevant clinical data donated by cancer patients. These biosamples are stored in a secure repository and researchers can apply to use them. We make anonymized biosamples and data available for scientifically and ethically approved research on a cost-recovery basis. onCore UK works with other cancer biobanks in the UK via the NCRI Confederation of Cancer Biobanks (CCB), and with other biobanks internationally, to improve access for researchers to larger numbers of high quality biosamples, to harmonize how biobanks work and to share expertise for the benefit of all involved.

Proper citation: onCore UK (RRID:SCR_004348) Copy   

•   Source: SciCrunch Registry
  

http://hapmap.ncbi.nlm.nih.gov/

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. A multi-country collaboration among scientists and funding agencies to develop a public resource where genetic similarities and differences in human beings are identified and catalogued. Using this information, researchers will be able to find genes that affect health, disease, and individual responses to medications and environmental factors. All of the information generated by the Project will be released into the public domain. Their goal is to compare the genetic sequences of different individuals to identify chromosomal regions where genetic variants are shared. Public and private organizations in six countries are participating in the International HapMap Project. Data generated by the Project can be downloaded with minimal constraints. HapMap project related data, software, and documentation include: bulk data on genotypes, frequencies, LD data, phasing data, allocated SNPs, recombination rates and hotspots, SNP assays, Perlegen amplicons, raw data, inferred genotypes, and mitochondrial and chrY haplogroups; Generic Genome Browser software; protocols and information on assay design, genotyping and other protocols used in the project; and documentation of samples/individuals and the XML format used in the project.

Proper citation: International HapMap Project (RRID:SCR_002846) Copy   

•   Source: SciCrunch Registry
  

http://psidev.sourceforge.net/mi/xml/doc/user/index.html

The Proteomics Standards Initiative (PSI) aims to define community standards for data representation in proteomics to facilitate data comparison, exchange and verification. As a first step, the PSI is developing standards for two key areas of proteomics: mass spectrometry and protein-protein interaction data. The document describes the molecular interaction data exchange format. PSI is following a leveled approach to building this specification. Level 1 will describe protein interactions at a basic level that covers a large amount of currently available data. Subsequent levels will add capability to represent new molecular interaction information that the community wishes to exchange. The scope of PSI MI is currently limited to protein-protein interactions. Other molecules, such as small molecules, DNA and RNA maybe taken into account in the future. The PSI MI format is a data exchange format for protein-protein interactions. It is not a proposed database structure. The purpose of the document is to describe the general structure of the PSI MI XML specification in a more user-friendly manner than the specification does itself. PSI MI was designed by a group of people including representatives from database providers and users in both academia and industry. PSI MI is supported by the DIP, MINT, IntAct, BIND and HPRD databases.

Proper citation: PSI-MI (RRID:SCR_010710) Copy   

•   Source: SciCrunch Registry
  

http://www.anim.med.kyoto-u.ac.jp/nbr/default.aspx

NBRP-Rat was established to overcome limitations associated with properly utilizing existing rat resources. The collection of existing strains and genetic sub strains, phenotypic and genotypic characterization, cryopreservation of embryos, distribution of the collected rat strains, and a publicly accessible database of all assembled data are the major goals of this project. Once achieved, this unique database including the unique rat strains will become a powerful tool for biomedical research. A catalog of comparable, standardized and well characterized rat strains will lead to new and more precise research topics as well as it will facilitate biomedical sciences, drug discovery, advanced chemical research, and contributes to life sciences worldwide. As mentioned before, the major goals of NBRP-Rat are the collection, preservation and supply of rat strains. The repository includes strains from Japan and abroad, spontaneous mutants, congenic and recombinant strains as well as transgenic and mutagenized rats. Deposited rat strains are not only conserved as cryopreserved embryos and sperm. Many reference and frequently used rat strains are also maintained as living animals under SPF conditions. Furthermore, NBRP-rat provides a unique database on various rat strain phenotypes accompanied with basic genetic information. This allows scientists the selection of standardized and research specific strains. The animals themselves are provided free of charge to the research community (except for shipping costs). Sponsors: This project is one part of the National BioResource Projects (NBRP) in Japan for more than 20 species including animals, plants, microbes, tissues and DNAs. It is founded by the Japanese Ministry of Education, Culture, Sports, Science and Technology (Monkasho) and started in 2002.

Proper citation: National Bio Resource Project for the Rat. (RRID:SCR_012774) Copy   

•   Source: SciCrunch Registry
  

http://ocs.med.nyu.edu/immunohistochemistry

The Immunohistochemistry Core, a component of the Experimental Pathology Shared Resource, is located in Bellevue Hospital within the NYULMC Department of Pathology''s Anatomic Pathology clinical space. The laboratory serves as an immunohistochemical antibody repository with a catalog of over 900 antibodies. Antibodies are in stock and available for use in the core laboratory for the collection of experimental immunohistochemistry data. The laboratory develops immunohistochemical protocols for new antibodies (commercial or proprietary) that have not been tested in fresh, frozen, fixed human or animal tissues and cells. In addition to performing manual labeling, the laboratory is equipped with two Ventana NEXES and one Discovery automated immunohistochemical staining instruments. The laboratory uses human and animal tissue micro-arrays for validation and employs a wide variety of antigen retrieval methods for protocol development. The core offers tyramide and polymer amplification methods (manual) and single or two color chromogenic immunohistochemistry. The laboratory has also commenced developing protocols and validating antibodies for immunoflorescence in frozen and FFPE tissue samples. The laboratory faculty and staff are available to provide hands-on informal training, as well as guidance and support for the design and execution of experiments involving histopathology and immunohistochemistry of human and animal cells and tissues. In conjunction with the Histopathology Core Laboratory, the Immunohistochemistry Laboratory can also assist investigators with routine and advanced histopathologic services for tissue and cell specimens (including guidance on initial processing steps: grossing/tissue preparation, processing, embedding, paraffin/frozen microtomy) for samples destined for histopathological interpretation and analysis. In addition, we offer extensive options for special and routine histochemical and immunohistochemical labeling of both human and animal model cells and tissues.

Proper citation: NYU Immunohistochemistry Core (RRID:SCR_012721) Copy   

•   Source: SciCrunch Registry
  

http://www.bsc.gwu.edu/dpp/protocol.htmlvdoc

Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDKsample repository for DPP participants.

Proper citation: Diabetes Prevention Program Outcomes Study (RRID:SCR_001502) Copy   

•   Source: SciCrunch Registry
  

http://dbmi.mc.vanderbilt.edu/research/dnadatabank.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. BioVU is a research resource providing a View into biology at the level of DNA and other important macromolecules. BioVU has two major components. The first is a repository of DNA samples (extracted from discarded blood samples) that are coded solely by a Research Unique Identifier (RUI) derived from the Medical Record Number (MRN) using a one-way hash function. This is a computer algorithm that creates a transformation of each MRN such that the resulting RUI (which is in this instance is a 512 byte identifier) is unique, and has the property that it is not possible to infer or compute the MRN that generated it. As of early 2009, over 50,000 DNA samples were in the biobank, with new samples being added at the rate of approximately 700 per week. The second component of the resource is the creation of a database known as the Synthetic Derivative which is a collection of de-identified information extracted from VUMC''s electronic clinical information systems, indexed by the same one-way RUI used to track samples, and with content changed by deletion or permutation of all identifiers contained within each record. The Synthetic Derivative search interface is available to Vanderbilt researchers via the StarBRITE research portal created and maintained by the Vanderbilt Institute for Clinical and Translational Research. This user interface enables investigators meeting protocol approval criteria and other user agreement requirements to receive protocol-specific sets of data derived from DNA samples and from the Synthetic Derivative., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Vanderbilt BioVU (RRID:SCR_004632) Copy   

•   Source: SciCrunch Registry
  

http://c-path.org/programs/camd/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 8, 2022. Consortium developing new technologies and methods to accelerate the development and review of medical products for neurodegenerative diseases. It is focused on accelerating drug development for patients with chronic neurodegenerative disease, namely, Alzheimer's disease (AD) and Parkinson's disease (PD), by advancing drug development tools for evaluating drug efficacy, conducting clinical trials, and streamlining the process of regulatory review. The consortium focuses on sharing precompetitive patient-level data from the control arms of legacy clinical trials, developing new tools to be submitted to the regulatory agencies, and developing consensus data standards. CAMD has the following areas of focus: (1) qualification of biomarkers, (2) development of common data standards, (3) creation of integrated databases for clinical trials data, and (4) development of quantitative model-based tools for drug development. Regulatory milestones include a qualification opinion with EMA for the use of low baseline hippocampal volume for patient enrichment in pre-dementia trials, and most recently, positive regulatory decisions from the FDA and EMA for the use of a clinical trial simulation tool to aid in trials for mild to moderate stages of AD., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: CAMD (RRID:SCR_001389) Copy   

•   Source: SciCrunch Registry
  

http://dels.nas.edu/ilar

The mission of ILAR is to evaluate and disseminate information on issues related to the scientific, technological, and ethical use of animals and related biological resources in research, testing, and education. Using the principles of refinement, reduction, and replacement (3Rs) as a foundation, ILAR promotes high-quality science through the humane care and use of animals and the implementation of alternatives. Through the reports of expert committees, the ILAR Journal, web-based resources, and other means of communication, ILAR functions as a component of the National Academies to provide independent, objective advice to the federal government, the international biomedical research community, and the public. ILAR supports the responsible use of animals in research, testing, and education as a key component to advancing the health and quality of life of humans and animals. It promotes high-quality science and humane care and use of research animals based upon the principles of refinement, replacement, and reduction (the 3Rs) and high ethical standards. It fosters best practices that enhance human and animal welfare by organizing and disseminating information and by facilitating dialogue among interested parties. It has developed a unique Search Engine to search for animal models and strains. This search engine surveys all the websites of vendors and repositories of laboratory animals and biological material on our Links page. The ILAR develops guidelines on laboratory animal care and use and conducts conferences, symposia, and workshops on important laboratory animal problems. ILAR publishes the ILAR Journal on a quarterly basis, as well as conference proceedings and special reports prepared by committees of experts. A list of ILAR publications on issues related to laboratory animal research is available on the Web site. As part of the Animal Models and Genetic Stocks Information Exchange Program, ILAR staff members answer direct telephone and mail inquiries and maintain a Web page containing a database on animal models and genetic stock. The Web site also offers a comprehensive search engine that enables users to find information on the existence and location of special animal models, correct nomenclature to identify animals, and related topics such as diseases of animals and relevant publications. Sponsors: ILAR receives funding from the following sponsors: -Abbott Laboratories -Abbott Fund -American College of Laboratory Animal Medicine (ACLAM) -American Society of Laboratory Animal Practitioners (ASLAP) -Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) -Bristol-Myers Squibb Co. -Charles River -Charles River Laboratories Foundation -Covance -Federation of American Societies for Experimental Biology (FASEB) -GlaxoSmithKline -Merck & Co., Inc. -National Science Foundation (NSF) -Pfizer -Scientists Center for Animal Welfare (SCAW) -U.S. Department of Agriculture (USDA) -U.S. Department of the Army -U.S. Department of Health and Human Services (DHHS) :*National Institutes of Health (NIH) :*Office of Research Integrity (ORI) -U.S. Department of the Navy -U.S. Department of Veterans Affairs -Wellcome Trust -Wyeth Pharmaceuticals

Proper citation: Institute for Laboratory Animal Research (RRID:SCR_006872) Copy   

•   Source: SciCrunch Registry
  

http://jobs.newscientist.com/

At New Scientist Jobs you can search our database for hundreds of Science and Technology jobs from across the globe. Registration is free and you can upload your resume, set up email job alerts, subscribe to RSS feeds and apply for Science and Technology jobs online. Employers can post jobs. We also work in partnership with the science and academic community to help them recruit the right Science and Technology candidates for their vacancies online.

Proper citation: New Scientist Jobs (RRID:SCR_005155) Copy   

•   Source: SciCrunch Registry
  

http://www.ncbi.nlm.nih.gov/biosample

Database containing descriptions of biological source materials used in experimental assays. Sources include: GenBank, Sequence Read Archive (SRA), Coriell, ATCC. Submissions are supported by a web-based Submission Portal that guides users through a series of forms for input of rich metadata describing their samples. As the capacity and complexity of biological data sets expands, databases face new challenges in ensuring that the information is adequately organized and described. The NCBI BioSample database is being developed to help address the challenges by providing the means by which data generators can organize and describe a broad range of sample types, and link to corresponding sets of experimental data in archival databases.

Proper citation: NCBI BioSample (RRID:SCR_004854) Copy   

•   Source: SciCrunch Registry
  

http://www.australianphenomics.org.au/

Mouse models for the study of human and animal disease for Australian and international researchers. It has reduced the cost to researchers of accessing mouse models of disease, and provides equipment and expertise to undertake characterization and further research of these models. The APN brought together mouse production, strain storage and pathology capabilities, later extending the core services of the network, and include new services (RNAi and genomics services). Twelve Australian facilities and institutions currently constitute the APN. The APN partners contribute their expertise and infrastructure for the production of mouse models, as well as providing cryopreservation and pathology services. * Walter and Eliza Hall Institute of Medical Research * Monash University * Queensland Institute of Medical Research * Animal Resources Centre * Institute of Medical and Veterinary Science * University of Melbourne * Institute of Molecular Bioscience * Menzies Research Institute * Peter MacCallum Cancer Centre * Australian National University * Western Australian Institute of Medical Research * Centenary Institute In addition, the APN is working with the Atlas of Living Australia to develop a framework for Australia''''s e-science infrastructure to improve the capture, annotation and dissemination of research data. The APN''''s core expertise and infrastructure is also extended by key national and international partnerships. These include the Garvan Institute, the National Institutes of Health (United States), the Wellcome Trust (United Kingdom), and the University of Manitoba (Canada). Services * ES Cell to Mouse: Create a mouse model from embryonic stem cells * RNAi: Screen full genomes to identify novel gene targets * ENU Mutagenesis - Produce chemically-induced mouse models * Pathology - Investigate mouse models using clinical and histopathology * Genomics - Further mouse mutant identification via new discovery pipeline * NHMRC Australian PhenomeBank - a non-profit repository of mouse strains used in Medical Research.

Proper citation: Australian Phenomics Network (RRID:SCR_006150) Copy   

•   Source: SciCrunch Registry
  

http://www.nigms.nih.gov/

NIGMS supports basic biomedical research that is not targeted to specific diseases. NIGMS funds studies on genes, proteins, and cells, as well as on fundamental processes like communication within and between cells, how our bodies use energy, and how we respond to medicines. The results of this research increase our understanding of life and lay the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS also supports research training programs that produce the next generation of biomedical scientists, and it has special programs to encourage underrepresented minorities to pursue biomedical research careers. The National Institute of General Medical Sciences (NIGMS) primarily supports research that lays the foundation for advances in disease diagnosis, treatment, and prevention. The Institute's research training programs help provide the next generation of scientists. Each year, NIGMS-supported scientists make many advances in understanding fundamental life processes. In the course of answering basic research questions, these investigators increase our knowledge about the mechanisms and pathways involved in certain diseases. Institute grantees also develop important new tools and techniques, some of which have medical applications. In recognition of the significance of their work, a number of NIGMS grantees have received the Nobel Prize and other high scientific honors. At any given time, NIGMS supports approximately 4,700 research grants—approximately 11 percent of the grants funded by NIH as a whole. NIGMS also supports approximately 26 percent of the trainees who receive assistance from NIH. NIGMS also supports approximately 25% of the trainees who receive assistance from NIH. The Institute places great emphasis on supporting investigator-initiated research grants. It funds a limited number of research center grants in selected fields, including structural genomics, trauma and burn research, and systems biology. In addition, NIGMS supports several important scientific resources, including the NIGMS Human Genetic Cell Repository and the Protein Data Bank.

Proper citation: National Institute of General Medical Sciences (RRID:SCR_012887) Copy   

•   Source: SciCrunch Registry
  

https://clinicaltrials.gov/study/NCT00342927?term=AREA%5BBasicSearch%5D(NIDDK%20endocrine%20and%20diabetes)%20AND%20AREA%5BSponsorSearch%5D(NIDDK)%20AND%20AREA%5BOverallStatus%5D(NOT_YET_RECRUITING%20OR%20RECRUITING%20OR%20ACTIVE_NOT_RECRUITING)&rank=1

Multicenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal disease

Proper citation: Family Investigation of Nephropathy of Diabetes (RRID:SCR_001525) Copy   

•   Source: SciCrunch Registry